Mark Storey, a Radiation Oncologist at the Oklahoma Proton Center, expressed concerns about the effectiveness of the 340B Drug Pricing Program in wealthier states. He said that hospitals participating in the program often fail to adequately serve charity patients in these regions. The statement was made on X.
“In poor states, it seems to have value, while in wealthier states, 340b hospitals under serve charity patients,” said Storey.
The 340B Drug Pricing Program, established in 1992, allows eligible healthcare providers serving vulnerable populations to purchase outpatient drugs at reduced prices. According to the U.S. Government Accountability Office, the program is designed to stretch federal resources; however, oversight has been a persistent concern. Critics argue that some hospitals benefit financially without necessarily expanding patient care.
The Health Resources and Services Administration reported that by 2023, more than 12,700 covered entities were participating in the 340B program, with total drug sales under the program reaching $54 billion. This represents a significant increase from $30 billion in 2018, indicating an expanded footprint for the program.
According to a report from PhRMA (Pharmaceutical Research and Manufacturers of America), California’s 340B program has experienced notable growth. Hospitals in the state have maintained numerous partnerships with pharmacies. As of 2025, there are over 3,500 contracts between 340B hospitals and pharmacies in California, with approximately 40% involving out-of-state pharmacies. This trend has sparked discussions regarding whether the program aligns with its original intent.
Dr. Mark Storey is a board-certified Radiation Oncologist at Oklahoma Proton Center and received training from MD Anderson Cancer Center. His clinical philosophy emphasizes providing high-quality, patient-centered care using advanced radiation technologies. He has contributed to multiple studies on radiotherapy outcomes in prostate and breast cancer treatment.
